Additional Context: Early market building efforts for injectable PrEP with Long-acting Cabotegravir (CAB-LA) have been severely disrupted by funding cuts. By November 2025, only seven countries had procured CAB-LA elsewhere. Total LMIC CAB-LA initiations remain below 20,000. Countries’ strategies for delivering both injectable forms of PrEP vary, with some planning to phase out CAB-LA, while others are planning to deliver both injectable options.

Devex Researcher Note: Recent developments in long-acting treatment (LAT) are reshaping the global HIV response, particularly for the significant challenges in adherence and retention. CAB-LA is a highly effective, prescription-only injectable medication used as HIV pre-exposure prophylaxis (PrEP), preventing HIV infection in HIV-negative individuals at high risk, administered as a shot every two months instead of daily pills, offering a discreet, long-lasting alternative to oral PrEP for people who prefer not to take daily medication.

Source:Clinton Health Access Initiative,World Health Organization